CoChat

Amygdala activity after subchronic escitalopram administration in healthy volunteers: A pharmaco-functional magnetic resonance imaging study

Open access

The DOI matches its Crossref record; 98 of the 101 references it cites were found in a registry or an index; none of the 76 sources its claims cite is checked for support yet.

Abstract

Background: Selective serotonin reuptake inhibitors (SSRIs) are used for the treatment of several conditions including anxiety disorders, but the basic neurobiology of serotonin function remains unclear. The amygdala and prefrontal cortex are strongly innervated by serotonergic projections and have been suggested to play an important role in anxiety expression. However, serotonergic function in behaviour and SSRI-mediated neurobiological changes remain incompletely understood. Aims: To investigate the neural correlates of subchronic antidepressant administration. Methods: We investigated whether the 2- to 3-week administration of a highly selective SSRI (escitalopram) would alter brain activation on a task robustly shown to recruit the bilateral amygdala and frontal cortices in a large healthy volunteer sample. Participants performed the task during a functional magnetic resonance imaging acquisition before ( n = 96) and after subchronic escitalopram ( n = 46, days of administration mean (SD) = 15.7 (2.70)) or placebo ( n = 40 days of administration mean (SD) = 16.2 (2.90)) self-administration. Results: Compared to placebo, we found an elevation in right amygdala activation to the task after escitalopram administration without significant changes in mood. This effect was not seen in the left amygdala, the dorsomedial region of interest, the subgenual anterior cingulate cortex or the right fusiform area. There were no significant changes in connectivity between the dorsomedial cortex and amygdala or the subgenual anterior cingulate cortex after escitalopram administration. Conclusions: To date, this most highly powered study of subchronic SSRI administration indicates that, contrary to effects often seen in patients with anxiety disorders, subchronic SSRI treatment may increase amygdala activation in healthy controls. This finding highlights important gaps in our understanding of the functional role of serotonin.

Overview

CoChat Summary

## TL;DR

In this double-blind pharmaco-fMRI study of healthy volunteers, 2–3 weeks of 10 mg/day escitalopram increased right amygdala activation during emotional face processing compared with placebo. The treatment did not significantly change left amygdala, sgACC, dorsal ROI, or rFFA activation, and did not alter dorsal ROI connectivity with amygdala or sgACC.

## Key findings

  • At baseline, the task robustly activated the right amygdala, left amygdala, and rFFA, and deactivated the dorsal ROI and sgACC; for example, right amygdala activation had Cohen’s d = 1.17 and left amygdala d = 1.06.
  • After subchronic treatment, right amygdala activation was higher in the escitalopram group than placebo in the average-parameter analysis (linear regression adjusting for age, sex, and baseline activation: p = 0.034, Cohen’s d = 0.52).
  • There were no significant follow-up group differences in left amygdala (p = 0.13), dorsal ROI (p = 0.080), sgACC (p = 0.21), or rFFA (p = 0.19) activation.
  • Connectivity findings at baseline were replicated, but follow-up connectivity did not differ between groups for the dorsal ROI with either amygdala seed or sgACC; the paper reports no significant group differences and notes equivalent AFNI analyses were also null.

## Methods

  • Double-blind, repeated-measures, placebo-controlled design in healthy adults; participants completed fMRI before treatment and again after 12–23 days of self-administered escitalopram or placebo.
  • Sample: 98 recruited; final baseline analysis n = 96. Follow-up included n = 46 escitalopram and n = 40 placebo in the abstract, with an intention-to-treat follow-up sample of total n = 86 reported later.
  • Main task/analysis: an emotional face-processing block task (happy, fearful, neutral faces vs fixation cross) during fMRI; activation and generalized psychophysiological interaction connectivity were analyzed with ROI-based models in R and sensitivity analyses with AFNI small-volume correction.

## Limitations

  • The paper states that compliance was assessed by self-report only, “so some non-adherence may have been present.”
  • The authors state that results from healthy volunteers “may not generalise to patient populations.”
  • Evident from the text: the follow-up sample was smaller than baseline because 8 participants withdrew or had technical issues and 2 were excluded for excessive motion, which limits power and comparability across timepoints.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/02698811241286773

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Figures

Figure 1. Schematic of the emotional face processing task. Participants viewed blocks of happy, fearful and neutral faces, separated by a fixation cross. There were 12 blocks of stimuli in total, and four of each emotion. Participants were instructed to label the gender of the faces displayed via button press.
Figure 1. Schematic of the emotional face processing task. Participants viewed blocks of happy, fearful and neutral faces, separated by a fixation cross. There were 12 blocks of stimuli in total, and four of each emotion. Participants were instructed to label the gender of the faces displayed via button press.CC BY · PubMed Central
Figure 2. Activation changes during emotional face processing (faces vs fixation cross: red-yellow colour indicates increases, blue decreases) were seen within the (a) bilateral amygdala, (b) dorsal ROI and (c) sgACC. These baseline changes were recapitulated in the betas extracted from (d) the right amygdala, (e) the left amygdala, (f) dorsal ROI and (g) the sgACC. Significantly increased activation of the task was seen (h) in the right amygdala after subchronic escitalopram administration, but not within the (i) left amygdala, (j) dorsal ROI (although there was a trend level increase) and (k) sgACC. Significant results were considered at pSVC < 0.05 (small volume-corrected analyses) and p < 0.05 (average parameter analyses).
Figure 2. Activation changes during emotional face processing (faces vs fixation cross: red-yellow colour indicates increases, blue decreases) were seen within the (a) bilateral amygdala, (b) dorsal ROI and (c) sgACC. These baseline changes were recapitulated in the betas extracted from (d) the right amygdala, (e) the left amygdala, (f) dorsal ROI and (g) the sgACC. Significantly increased activation of the task was seen (h) in the right amygdala after subchronic escitalopram administration, but not within the (i) left amygdala, (j) dorsal ROI (although there was a trend level increase) and (k) sgACC. Significant results were considered at pSVC < 0.05 (small volume-corrected analyses) and p < 0.05 (average parameter analyses).CC BY · PubMed Central
Figure 3. Significant connectivity (gPPI β value) during emotional face processing (faces vs fixation cross) between the dorsal ROI and (a) the right amygdala (but not (b) the left amygdala) and (c) the sgACC. No significant changes in connectivity between the dorsal ROI and the (d) right amygdala, (e) left amygdala or (f) sgACC were seen following subchronic escitalopram administration. (g) The dorsal ROI mask was used for these analyses. Significant results were considered at pSVC < 0.05 (small volume-corrected analyses) and p < 0.05 (average parameter analyses).
Figure 3. Significant connectivity (gPPI β value) during emotional face processing (faces vs fixation cross) between the dorsal ROI and (a) the right amygdala (but not (b) the left amygdala) and (c) the sgACC. No significant changes in connectivity between the dorsal ROI and the (d) right amygdala, (e) left amygdala or (f) sgACC were seen following subchronic escitalopram administration. (g) The dorsal ROI mask was used for these analyses. Significant results were considered at pSVC < 0.05 (small volume-corrected analyses) and p < 0.05 (average parameter analyses).CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 41 Not checked · 60 Own results and interpretations

38 more claims

Create a free account to see all 101 claims and to verify the 76 references still open.

See all claims — free account
  • The quote only partly states this claim. 2
  • It may state two separate claims as one. 25
  • Probably not a substantial claim. 43

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 98 references

Research works printed but not linked: 2

  1. Beck AT, Steer RA, Brown GK (1996) Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation.
  2. Spielberger CD, Gorsuch RL, Lushene R, et al. (1983) Manual for the State-Trait Anxiety Scale. Washington, DC Consulting Psychologists Press.

Cited by

See all 3

Metadata

Authors
Lukow, P. B., Lowther, M., Pike, A. C., Yamamori, Y., Chavanne, A. V., Gormley, S., Aylward, J., McCloud, T., Goble, T., Rodriguez-Sanchez, J., Tuominen, E. W., Buehler, S. K., Kirk, P., & Robinson, O. J.
Affiliations
  • University College London (GB)
  • École Normale Supérieure Paris-Saclay (FR)
  • National Institute of Mental Health (US)
Corresponding author
Lukow, Paulina B
Venue
Journal of Psychopharmacology
Published
2024-10-04
Volume
38
Issue
12
Pages
1071-1082
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W4403129586
Cited by
3
References
101
Citations by year
2025: 3
FWCI
0.52
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Psychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
  • City Research Online (City University London) (submittedVersion)
  • edoc Publication server (Humboldt University of Berlin) (submittedVersion, cc-by)
  • edoc Publication server (Humboldt University of Berlin) (cc-by)
Funders
Medical Research Council (MR/R020817/R)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
Keywords
escitalopram, amygdala activation, selective serotonin reuptake inhibitors, serotonin function, anxiety, healthy volunteers, prefrontal cortex, subgenual anterior cingulate cortex
MeSH terms
Escitalopram, Adult, Amygdala, Double-Blind Method, Female, Humans, Magnetic Resonance Imaging, Male, Citalopram, Selective Serotonin Reuptake Inhibitors, Prefrontal Cortex, Young Adult, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amygdala activity after subchronic escitalopram administration in healthy volunteers: A pharmaco-functional magnetic resonance imaging study. https://app.cochat.ai/papers/10.1177/02698811241286773
The paper
Lukow, P. B., Lowther, M., Pike, A. C., Yamamori, Y., Chavanne, A. V., Gormley, S., Aylward, J., McCloud, T., Goble, T., Rodriguez-Sanchez, J., Tuominen, E. W., Buehler, S. K., Kirk, P., & Robinson, O. J. (2024). Amygdala activity after subchronic escitalopram administration in healthy volunteers: A pharmaco-functional magnetic resonance imaging study. Journal of Psychopharmacology. https://doi.org/10.1177/02698811241286773

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.